At the NCCN 2022 Annual Conference, Anthony Mato, MD, MSCE, discussed the use of targeted therapies for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Question 1 of 5
Among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), the use of targeted treatment agents has led to improvements in:
